Latest Pradaxa Lawsuit Updates: Cases Moved to Federal Court

Share Article

The Pradaxa Resource Center is the Web’s largest source for information on Pradaxa research, side effects and legal news. Visit http://www.Pradaxa-lawsuits.org

Pradaxa Diagram
Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

The Pradaxa Resource Center, a patient advocacy group, is alerting patients who have suffered internal bleeding after taking the drug Pradaxa that a judicial panel has now consolidated all lawsuits to one federal court, which will expedite litigation for victims.

Anyone who has suffered internal bleeding or had a loved one affected by taking Pradaxa is encouraged to speak with a lawyer about their legal rights as soon as possible.

Pradaxa is a popular blood thinning drug prescribed to prevent strokes and blood clots in patients with atrial fibrillation. Although only on the market since October, 2010, Pradaxa sold over $1 billion for the year ending February, 2012, according to a Wall Street Journal report on April 24, 2012.

On December 7, 2011, however, the FDA warned patients that they would launch an investigation after receiving more injury or death reports from Pradaxa than expected. The Institute for Safe Medication Practices also reported on June 6, 2012 that Pradaxa led all other medications in 2011 for reports of death or bleeding to the FDA.

Due to the number of lawsuits expected over Pradaxa bleeding injury or death, lawyers requested that all cases be moved to one central federal court. The case is known as MDL No. 2385 IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.

After hearing arguments from lawyers who expect more than 500 cases, the United States Judicial Panel on Multidistrict Litigation (JPML) issued an order on August 8, 2012 consolidating Pradaxa lawsuits to the Southern District of Illinois.

On July 25th, Judge David Herndon, who will oversee the federal litigation, issued an order (http://www.ilsd.uscourts.gov/opinions/ilsd_live.3.12.cv.616.2108177.0.pdf) denying attempts by drug maker Boehringer Ingelheim to dismiss Pradaxa bleeding lawsuits. Although the manufacturer argued that the drug label warned of internal bleeding, Judge Herndon ruled that this did not address the risk of uncontrollable bleeding and the lack of a reversal agent.

The Pradaxa Resource Center believes moving all Pradaxa lawsuits into one federal court will expedite the litigation process and help victims share in valuable evidence. However, due to the specialized nature of these federal MDL cases, victims should make sure any lawyer they choose has experience in this type of litigation.

Those affected by a Pradaxa injury are urged to speak with a lawyer about their legal options. The Pradaxa Resource center works only with lawyers who are already handling Pradaxa lawsuits.

For more information on the research, warnings, Pradaxa side effects and legal options relating to the drug Pradaxa, or to speak with a lawyer, visit http://www.Pradaxa-lawsuits.org.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Schroeder
Visit website